0	0	1999-09-21	CD	O	O	B-Num
0	1	21	CD	O	O	B-Num
0	2	:	:	O	O	I-Num
0	3	30	CD	O	B-NP	I-Num
0	4	DRUG	NN	O	I-NP	O
0	5	AGENCY	NN	O	I-NP	O
0	6	APPROVES	VBZ	O	B-VP	O
0	7	ANTIBIOTIC	NNP	O	O	O

1	0	WASHINGTON	NNP	O	O	B-LocStat
1	1	_	NN	O	O	O
1	2	With	IN	O	B-PP	O
1	3	drug-resistant	JJ	O	B-NP	O
1	4	bacteria	NNS	O	I-NP	B-Medical
1	5	on	IN	O	B-PP	O
1	6	the	DT	O	B-NP	O
1	7	rise	NN	O	I-NP	O
1	8	COMMA	COMMA	O	O	O
1	9	doctors	NNS	O	B-NP	B-ProfTitle
1	10	have	VBP	O	B-VP	O
1	11	watched	VBN	O	I-VP	O
1	12	helplessly	RB	O	O	O
1	13	as	IN	O	O	O
1	14	patients	NNS	O	B-NP	O
1	15	died	VBD	O	B-VP	O
1	16	from	IN	O	B-PP	O
1	17	germs	NNS	O	B-NP	O
1	18	that	IN	O	O	O
1	19	cannot	NN	O	B-NP	O
1	20	be	VB	O	B-VP	O
1	21	cured	VBN	O	I-VP	O
1	22	by	IN	O	B-PP	O
1	23	vancomycin	NN	O	B-NP	O
1	24	COMMA	COMMA	O	O	O
1	25	long	RB	O	O	O
1	26	considered	VBD	O	B-VP	O
1	27	the	DT	O	B-NP	O
1	28	antibiotic	NN	O	I-NP	B-Medical
1	29	of	IN	O	B-PP	O
1	30	last	JJ	O	B-NP	O
1	31	resort	NN	O	I-NP	O
1	32	.	.	O	O	O

2	0	Tuesday	NNP	O	B-NP	B-Peop
2	1	COMMA	COMMA	O	O	O
2	2	the	DT	O	B-NP	O
2	3	Food	NNP	O	I-NP	B-Food
2	4	and	CC	O	I-NP	O
2	5	Drug	NNP	O	I-NP	B-Peop
2	6	Administration	NNP	O	I-NP	I-Peop
2	7	approved	VBD	O	B-VP	O
2	8	a	DT	O	B-NP	O
2	9	new	JJ	O	I-NP	O
2	10	antibiotic	NN	O	I-NP	B-Medical
2	11	that	WDT	O	B-NP	O
2	12	promises	VBZ	O	B-VP	O
2	13	to	TO	O	I-VP	O
2	14	rescue	VB	O	I-VP	O
2	15	some	DT	O	B-NP	O
2	16	patients	NNS	O	I-NP	O
2	17	when	WRB	O	O	O
2	18	vancomycin	NN	O	B-NP	O
2	19	fails	VBZ	O	B-VP	O
2	20	.	.	O	O	O

3	0	The	DT	O	B-NP	O
3	1	drug	NN	O	I-NP	B-Medical
3	2	COMMA	COMMA	O	O	O
3	3	Synercid	NNP	O	B-NP	O
3	4	COMMA	COMMA	O	O	O
3	5	manufactured	VBN	O	B-VP	O
3	6	by	IN	O	B-PP	O
3	7	Rhone-Poulenc	NNP	O	B-NP	B-OrgCorp
3	8	Rorer	NNP	O	I-NP	I-OrgCorp
3	9	Inc.	NNP	O	I-NP	I-OrgCorp
3	10	COMMA	COMMA	O	O	O
3	11	is	VBZ	O	B-VP	O
3	12	not	RB	O	O	O
3	13	a	DT	O	B-NP	O
3	14	panacea	NN	O	I-NP	O
3	15	for	IN	O	B-PP	O
3	16	antibiotic	NN	O	B-NP	B-Medical
3	17	resistance	NN	O	I-NP	O
3	18	.	.	O	O	O

4	0	It	PRP	O	B-NP	O
4	1	is	VBZ	O	B-VP	O
4	2	effective	VBN	O	I-VP	O
4	3	only	RB	O	O	O
4	4	against	IN	O	B-PP	O
4	5	a	DT	O	B-NP	O
4	6	handful	NN	O	I-NP	O
4	7	of	IN	O	B-PP	O
4	8	disease-causing	JJ	O	B-NP	O
4	9	microbes	NNS	O	I-NP	O
4	10	COMMA	COMMA	O	O	O
4	11	and	CC	O	O	O
4	12	does	VBZ	O	B-VP	O
4	13	not	RB	O	I-VP	O
4	14	work	VB	O	I-VP	O
4	15	in	IN	O	B-PP	O
4	16	all	DT	O	B-NP	O
4	17	cases	NNS	O	I-NP	O
4	18	.	.	O	O	O

5	0	And	CC	O	O	O
5	1	experts	NNS	O	B-NP	O
5	2	worry	VBP	O	B-VP	O
5	3	that	DT	O	O	O
5	4	resistance	NN	O	B-NP	O
5	5	to	TO	O	B-PP	O
5	6	Synercid	NNP	O	B-NP	B-Peop
5	7	could	MD	O	B-VP	O
5	8	develop	VB	O	I-VP	O
5	9	as	RB	O	O	O
5	10	well	RB	O	O	O
5	11	.	.	O	O	O

6	0	But	CC	O	O	O
6	1	the	DT	O	B-NP	O
6	2	drug	NN	O	I-NP	B-Medical
6	3	could	MD	O	B-VP	O
6	4	be	VB	O	I-VP	O
6	5	a	DT	O	B-NP	O
6	6	lifesaver	NN	O	I-NP	O
6	7	for	IN	O	B-PP	O
6	8	some	DT	O	B-NP	O
6	9	of	IN	O	B-PP	O
6	10	the	DT	O	B-NP	O
6	11	16COMMA000	CD	O	I-NP	B-Num
6	12	hospital	NN	O	I-NP	O
6	13	patients	NNS	O	I-NP	O
6	14	who	WP	O	B-NP	O
6	15	become	VBP	O	B-VP	O
6	16	infected	VBN	O	I-VP	O
6	17	each	DT	O	B-NP	O
6	18	year	NN	O	I-NP	O
6	19	with	IN	O	B-PP	O
6	20	a	DT	O	B-NP	O
6	21	resistant	JJ	O	I-NP	O
6	22	strain	NN	O	I-NP	O
6	23	of	IN	O	B-PP	O
6	24	the	DT	O	B-NP	O
6	25	enterococcus	NN	O	I-NP	O
6	26	bacterium	NN	O	I-NP	O
6	27	COMMA	COMMA	O	O	O
6	28	enterococcus	NN	O	B-NP	O
6	29	faecium	NN	O	I-NP	O
6	30	COMMA	COMMA	O	O	O
6	31	that	DT	O	B-NP	O
6	32	has	VBZ	O	B-VP	O
6	33	emerged	VBD	O	I-VP	O
6	34	over	IN	O	B-PP	O
6	35	the	DT	O	B-NP	O
6	36	past	JJ	O	I-NP	O
6	37	decade	NN	O	I-NP	O
6	38	.	.	O	O	O

7	0	And	CC	O	O	O
7	1	so	IN	O	O	O
7	2	the	DT	O	B-NP	O
7	3	federal	JJ	O	I-NP	O
7	4	agency	NN	O	I-NP	B-OrgCorp
7	5	gave	VBD	O	B-VP	O
7	6	the	DT	O	B-NP	O
7	7	drug	NN	O	I-NP	B-Medical
7	8	fast-track	JJ	O	I-NP	O
7	9	approval	NN	O	I-NP	O
7	10	COMMA	COMMA	O	O	O
7	11	permitting	VBG	O	B-VP	O
7	12	the	DT	O	B-NP	O
7	13	company	NN	O	I-NP	B-OrgCorp
7	14	to	TO	O	B-VP	O
7	15	market	VB	O	I-VP	O
7	16	it	PRP	O	B-NP	O
7	17	even	RB	O	O	O
7	18	though	IN	O	O	O
7	19	tests	NNS	O	B-NP	O
7	20	of	IN	O	B-PP	O
7	21	its	PP$	O	B-NP	O
7	22	effectiveness	NN	O	I-NP	O
7	23	are	VBP	O	B-VP	O
7	24	still	RB	O	I-VP	O
7	25	going	VBG	O	I-VP	O
7	26	on	IN	O	O	O
7	27	.	.	O	O	O

8	0	``	``	O	O	O
8	1	This	DT	O	B-NP	O
8	2	is	VBZ	O	B-VP	O
8	3	an	DT	O	B-NP	O
8	4	important	JJ	O	I-NP	O
8	5	drug	NN	O	I-NP	B-Medical
8	6	to	TO	O	B-VP	O
8	7	help	VB	O	I-VP	O
8	8	patients	NNS	O	B-NP	O
8	9	who	WP	O	B-NP	O
8	10	have	VBP	O	B-VP	O
8	11	no	DT	O	B-NP	O
8	12	alternative	NN	O	I-NP	B-Medical
8	13	therapiesCOMMA	NN	O	I-NP	O
8	14	''	''	O	O	O
8	15	said	VBD	O	B-VP	O
8	16	Dr.	NNP	O	B-NP	B-ProfTitle
8	17	Sandra	NNP	O	I-NP	B-Peop
8	18	Kweder	NNP	O	I-NP	I-Peop
8	19	COMMA	COMMA	O	O	O
8	20	who	WP	O	B-NP	O
8	21	heads	VBZ	O	B-VP	O
8	22	the	DT	O	B-NP	O
8	23	drug	NN	O	I-NP	B-Medical
8	24	agency	NN	O	I-NP	B-OrgCorp
8	25	's	POS	O	B-NP	O
8	26	division	NN	O	I-NP	O
8	27	that	DT	O	B-NP	O
8	28	evaluates	VBZ	O	B-VP	O
8	29	new	JJ	O	B-NP	O
8	30	antibiotics	NNS	O	I-NP	O
8	31	.	.	O	O	O

9	0	She	PRP	O	B-NP	O
9	1	urged	VBD	O	B-VP	O
9	2	doctors	NNS	O	B-NP	B-ProfTitle
9	3	to	TO	O	B-VP	O
9	4	use	VB	O	I-VP	O
9	5	Synercid	NNP	O	B-NP	B-Peop
9	6	``	``	O	O	O
9	7	judiciously	RB	O	O	O
9	8	in	IN	O	O	O
9	9	order	NN	O	O	O
9	10	to	TO	O	B-VP	O
9	11	attempt	VB	O	I-VP	O
9	12	to	TO	O	I-VP	O
9	13	minimize	VB	O	I-VP	O
9	14	the	DT	O	B-NP	O
9	15	likelihood	NN	O	I-NP	O
9	16	of	IN	O	B-PP	O
9	17	widespread	JJ	O	B-NP	O
9	18	resistance	NN	O	I-NP	O
9	19	to	TO	O	B-PP	O
9	20	this	DT	O	B-NP	O
9	21	drug	NN	O	I-NP	B-Medical
9	22	as	RB	O	O	O
9	23	well	RB	O	O	O
9	24	.	.	O	O	O
9	25	''	''	O	O	O

10	0	For	IN	O	B-PP	O
10	1	the	DT	O	B-NP	O
10	2	past	JJ	O	I-NP	O
10	3	10	CD	O	I-NP	B-Num
10	4	years	NNS	O	I-NP	I-Num
10	5	COMMA	COMMA	O	O	O
10	6	scientists	NNS	O	B-NP	B-ProfTitle
10	7	at	IN	O	B-PP	O
10	8	the	DT	O	B-NP	O
10	9	Centers	NNPS	O	I-NP	B-Loc
10	10	for	IN	O	B-PP	O
10	11	Disease	NNP	O	B-NP	B-Peop
10	12	Control	NNP	O	I-NP	I-Peop
10	13	and	CC	O	O	O
10	14	Prevention	NNP	O	B-NP	O
10	15	and	CC	O	O	O
10	16	elsewhere	RB	O	O	O
10	17	have	VBP	O	B-VP	O
10	18	been	VBN	O	I-VP	O
10	19	sounding	VBG	O	I-VP	O
10	20	alarms	NNS	O	B-NP	O
10	21	about	IN	O	B-PP	O
10	22	the	DT	O	B-NP	O
10	23	growth	NN	O	I-NP	O
10	24	of	IN	O	B-PP	O
10	25	antibiotic	NN	O	B-NP	B-Medical
10	26	resistance	NN	O	I-NP	O
10	27	COMMA	COMMA	O	O	O
10	28	a	DT	O	B-NP	O
10	29	problem	NN	O	I-NP	O
10	30	that	WDT	O	B-NP	O
10	31	is	VBZ	O	B-VP	O
10	32	particularly	RB	O	O	O
10	33	prevalent	JJ	O	O	O
10	34	in	IN	O	B-PP	O
10	35	hospitals	NNS	O	B-NP	O
10	36	COMMA	COMMA	O	O	O
10	37	where	WRB	O	O	O
10	38	microbes	NNS	O	B-NP	O
10	39	spread	VBP	O	B-VP	O
10	40	quickly	RB	O	O	O
10	41	and	CC	O	O	O
10	42	attack	VBP	O	B-VP	O
10	43	the	DT	O	B-NP	O
10	44	elderly	JJ	O	I-NP	O
10	45	COMMA	COMMA	O	O	O
10	46	people	NNS	O	B-NP	O
10	47	with	IN	O	B-PP	O
10	48	weak	JJ	O	B-NP	O
10	49	immune	JJ	O	I-NP	B-Medical
10	50	systems	NNS	O	I-NP	O
10	51	and	CC	O	O	O
10	52	other	JJ	O	B-NP	O
10	53	vulnerable	JJ	O	I-NP	O
10	54	patients	NNS	O	I-NP	O
10	55	.	.	O	O	O

11	0	Vancomycin-resistant	JJ	O	B-NP	O
11	1	enterococcus	NN	O	I-NP	O
11	2	faecium	NN	O	I-NP	O
11	3	COMMA	COMMA	O	O	O
11	4	which	WDT	O	B-NP	O
11	5	goes	VBZ	O	B-VP	O
11	6	by	IN	O	B-PP	O
11	7	the	DT	O	B-NP	O
11	8	scientific	JJ	O	I-NP	O
11	9	acronym	NN	O	I-NP	O
11	10	VREF	NNP	O	I-NP	O
11	11	and	CC	O	O	O
11	12	is	VBZ	O	B-VP	O
11	13	a	DT	O	B-NP	O
11	14	leading	VBG	O	I-NP	O
11	15	cause	NN	O	I-NP	O
11	16	of	IN	O	B-PP	O
11	17	infections	NNS	O	B-NP	O
11	18	from	IN	O	B-PP	O
11	19	surgical	JJ	O	B-NP	B-Medical
11	20	wounds	NNS	O	I-NP	O
11	21	COMMA	COMMA	O	O	O
11	22	on	IN	O	B-PP	O
11	23	the	DT	O	B-NP	O
11	24	skin	NN	O	I-NP	O
11	25	and	CC	O	B-PP	O
11	26	in	IN	O	B-PP	O
11	27	the	DT	O	B-NP	O
11	28	urinary	JJ	O	I-NP	O
11	29	tract	NN	O	I-NP	B-Medical
11	30	COMMA	COMMA	O	O	O
11	31	was	VBD	O	B-VP	O
11	32	first	RB	O	O	B-Num
11	33	reported	VBD	O	B-VP	O
11	34	in	IN	O	B-PP	O
11	35	this	DT	O	B-NP	O
11	36	country	NN	O	I-NP	O
11	37	in	IN	O	B-PP	O
11	38	1989	CD	O	B-NP	B-Date
11	39	.	.	O	O	O

12	0	By	IN	O	B-PP	O
12	1	1997	CD	O	B-NP	B-Date
12	2	COMMA	COMMA	O	O	O
12	3	according	VBG	O	B-PP	O
12	4	to	TO	O	B-PP	O
12	5	the	DT	O	B-NP	O
12	6	centers	NNS	O	I-NP	O
12	7	COMMA	COMMA	O	O	O
12	8	more	JJR	O	B-NP	O
12	9	than	IN	O	I-NP	O
12	10	half	DT	O	I-NP	O
12	11	of	IN	O	B-PP	O
12	12	all	PDT	O	B-NP	O
12	13	enterococcus	NN	O	I-NP	O
12	14	faecium	NN	O	I-NP	O
12	15	strains	NNS	O	I-NP	O
12	16	could	MD	O	B-VP	O
12	17	not	RB	O	I-VP	O
12	18	be	VB	O	I-VP	O
12	19	treated	VBN	O	I-VP	O
12	20	with	IN	O	B-PP	O
12	21	vancomycin	NN	O	B-NP	O
12	22	.	.	O	O	O

13	0	Dr.	NNP	O	B-NP	B-ProfTitle
13	1	David	NNP	O	I-NP	B-Peop
13	2	M.	NNP	O	I-NP	I-Peop
13	3	Bell	NNP	O	I-NP	I-Peop
13	4	COMMA	COMMA	O	O	O
13	5	who	WP	O	B-NP	O
13	6	coordinates	VBZ	O	B-VP	O
13	7	antibiotic	NN	O	B-NP	B-Medical
13	8	resistance	NN	O	I-NP	O
13	9	programs	NNS	O	I-NP	O
13	10	for	IN	O	B-PP	O
13	11	the	DT	O	B-NP	O
13	12	centers	NNS	O	I-NP	O
13	13	COMMA	COMMA	O	O	O
13	14	called	VBD	O	B-VP	O
13	15	the	DT	O	B-NP	O
13	16	approval	NN	O	I-NP	O
13	17	of	IN	O	B-PP	O
13	18	Synercid	NNP	O	B-NP	B-Peop
13	19	``	``	O	O	O
13	20	very	RB	O	B-NP	O
13	21	good	JJ	O	I-NP	O
13	22	news	NN	O	I-NP	O
13	23	''	''	O	O	O
13	24	for	IN	O	B-PP	O
13	25	patients	NNS	O	B-NP	O
13	26	with	IN	O	B-PP	O
13	27	the	DT	O	B-NP	O
13	28	infections	NNS	O	I-NP	O
13	29	.	.	O	O	O

14	0	In	IN	O	B-PP	O
14	1	addition	NN	O	B-NP	O
14	2	to	TO	O	B-PP	O
14	3	being	VBG	O	B-VP	O
14	4	the	DT	O	B-NP	O
14	5	first	JJ	O	I-NP	B-Num
14	6	alternative	NN	O	I-NP	B-Medical
14	7	to	TO	O	B-PP	O
14	8	vancomycin	NN	O	B-NP	O
14	9	in	IN	O	B-PP	O
14	10	30	CD	O	B-NP	B-Num
14	11	years	NNS	O	I-NP	I-Num
14	12	COMMA	COMMA	O	O	O
14	13	Synercid	NNP	O	B-NP	B-Peop
14	14	is	VBZ	O	B-VP	O
14	15	the	DT	O	B-NP	O
14	16	first	JJ	O	I-NP	B-Num
14	17	drug	NN	O	I-NP	B-Medical
14	18	in	IN	O	B-PP	O
14	19	the	DT	O	B-NP	O
14	20	class	NN	O	I-NP	O
14	21	known	VBN	O	B-VP	O
14	22	as	IN	O	B-PP	O
14	23	streptogramins	NNS	O	B-NP	O
14	24	to	TO	O	B-VP	O
14	25	be	VB	O	I-VP	O
14	26	approved	VBN	O	I-VP	O
14	27	for	IN	O	B-PP	O
14	28	sale	NN	O	B-NP	O
14	29	in	IN	O	B-PP	O
14	30	the	DT	O	B-NP	O
14	31	United	NNP	O	I-NP	B-LocCoun
14	32	States	NNPS	O	I-NP	I-LocCoun
14	33	.	.	O	O	O

15	0	The	DT	O	B-NP	O
15	1	drug	NN	O	I-NP	B-Medical
15	2	is	VBZ	O	B-VP	O
15	3	given	VBN	O	I-VP	O
15	4	by	IN	O	B-PP	O
15	5	injection	NN	O	B-NP	B-Medical
15	6	only	RB	O	O	O
15	7	;	:	O	O	O
15	8	it	PRP	O	B-NP	O
15	9	will	MD	O	B-VP	O
15	10	cost	VB	O	I-VP	O
15	11	hospitals	NNS	O	B-NP	O
15	12	$85	NN	O	I-NP	B-Money
15	13	a	DT	O	B-NP	O
15	14	dose	NN	O	I-NP	B-Medical
15	15	and	CC	O	O	O
15	16	will	MD	O	B-VP	O
15	17	be	VB	O	I-VP	O
15	18	available	JJ	O	O	O
15	19	next	JJ	O	B-NP	O
15	20	week	NN	O	I-NP	O
15	21	COMMA	COMMA	O	O	O
15	22	a	DT	O	B-NP	O
15	23	spokesman	NN	O	I-NP	O
15	24	for	IN	O	B-PP	O
15	25	the	DT	O	B-NP	O
15	26	manufacturer	NN	O	I-NP	B-ProfTitle
15	27	said	VBD	O	B-VP	O
15	28	.	.	O	O	O

16	0	Rhone-Poulenc	NNP	O	B-NP	B-OrgCorp
16	1	has	VBZ	O	B-VP	O
16	2	been	VBN	O	I-VP	O
16	3	making	VBG	O	I-VP	O
16	4	Synercid	NNP	O	B-NP	O
16	5	available	JJ	O	O	O
16	6	in	IN	O	B-PP	O
16	7	emergencies	NNS	O	B-NP	O
16	8	to	TO	O	B-VP	O
16	9	treat	VB	O	I-VP	O
16	10	VREF	NNP	O	B-NP	O
16	11	infections	NNS	O	I-NP	O
16	12	since	IN	O	B-PP	O
16	13	1993	CD	O	B-NP	B-Date
16	14	;	:	O	O	O
16	15	so	RB	O	O	O
16	16	far	RB	O	O	O
16	17	COMMA	COMMA	O	O	O
16	18	the	DT	O	B-NP	O
16	19	company	NN	O	I-NP	B-OrgCorp
16	20	said	VBD	O	B-VP	O
16	21	COMMA	COMMA	O	O	O
16	22	7COMMA000	CD	O	B-NP	B-Num
16	23	patients	NNS	O	I-NP	O
16	24	around	IN	O	B-PP	O
16	25	the	DT	O	B-NP	O
16	26	world	NN	O	I-NP	O
16	27	have	VBP	O	B-VP	O
16	28	received	VBN	O	I-VP	O
16	29	the	DT	O	B-NP	O
16	30	drug	NN	O	I-NP	B-Medical
16	31	COMMA	COMMA	O	O	O
16	32	including	VBG	O	B-PP	O
16	33	5COMMA000	CD	O	B-NP	B-Num
16	34	in	IN	O	B-PP	O
16	35	the	DT	O	B-NP	O
16	36	United	NNP	O	I-NP	B-LocCoun
16	37	States	NNPS	O	I-NP	I-LocCoun
16	38	.	.	O	O	O

17	0	But	CC	O	O	O
17	1	conducting	VBG	O	B-VP	O
17	2	rigorous	JJ	O	B-NP	O
17	3	scientific	JJ	O	I-NP	O
17	4	tests	NNS	O	I-NP	O
17	5	of	IN	O	B-PP	O
17	6	Synercid	NNP	O	B-NP	B-Peop
17	7	's	POS	O	B-NP	O
17	8	effectiveness	NN	O	I-NP	O
17	9	has	VBZ	O	B-VP	O
17	10	proved	VBN	O	I-VP	O
17	11	tricky	JJ	O	O	O
17	12	COMMA	COMMA	O	O	O
17	13	said	VBD	O	B-VP	O
17	14	Dr.	NNP	O	B-NP	B-Peop
17	15	Kweder	NNP	O	I-NP	I-Peop
17	16	of	IN	O	B-PP	O
17	17	the	DT	O	B-NP	O
17	18	drug	NN	O	I-NP	B-Medical
17	19	agency	NN	O	I-NP	B-OrgCorp
17	20	COMMA	COMMA	O	O	O
17	21	in	IN	O	B-PP	O
17	22	part	NN	O	B-NP	O
17	23	because	IN	O	O	O
17	24	the	DT	O	B-NP	O
17	25	patients	NNS	O	I-NP	O
17	26	were	VBD	O	B-VP	O
17	27	so	RB	O	O	O
17	28	sick	JJ	O	O	O
17	29	they	PRP	O	B-NP	O
17	30	often	RB	O	O	O
17	31	died	VBD	O	B-VP	O
17	32	of	IN	O	B-PP	O
17	33	their	PP$	O	B-NP	O
17	34	underlying	VBG	O	I-NP	O
17	35	diseases	NNS	O	I-NP	O
17	36	COMMA	COMMA	O	O	O
17	37	and	CC	O	O	O
17	38	in	IN	O	B-PP	O
17	39	part	NN	O	B-NP	O
17	40	because	IN	O	O	O
17	41	there	EX	O	B-NP	O
17	42	is	VBZ	O	B-VP	O
17	43	no	DT	O	B-NP	O
17	44	other	JJ	O	I-NP	O
17	45	treatment	NN	O	I-NP	O
17	46	with	IN	O	B-PP	O
17	47	which	WDT	O	B-NP	O
17	48	to	TO	O	B-VP	O
17	49	compare	VB	O	I-VP	O
17	50	the	DT	O	B-NP	O
17	51	drug	NN	O	I-NP	B-Medical
17	52	.	.	O	O	O

18	0	Synercid	NNP	O	B-NP	B-Peop
18	1	was	VBD	O	B-VP	O
18	2	tested	VBN	O	I-VP	O
18	3	in	IN	O	B-PP	O
18	4	1COMMA222	CD	O	B-NP	B-Num
18	5	patients	NNS	O	I-NP	O
18	6	with	IN	O	B-PP	O
18	7	VREF	NNP	O	B-NP	B-Org
18	8	infections	NNS	O	I-NP	O
18	9	.	.	O	O	O

19	0	Overall	RB	O	O	O
19	1	COMMA	COMMA	O	O	O
19	2	the	DT	O	B-NP	O
19	3	drug	NN	O	I-NP	B-Medical
19	4	agency	NN	O	I-NP	B-OrgCorp
19	5	said	VBD	O	B-VP	O
19	6	COMMA	COMMA	O	O	O
19	7	the	DT	O	B-NP	O
19	8	antibiotic	NN	O	I-NP	B-Medical
19	9	proved	VBD	O	B-VP	O
19	10	effective	JJ	O	O	O
19	11	for	IN	O	B-PP	O
19	12	52	CD	O	B-NP	B-NumPercent
19	13	percent	NN	O	I-NP	I-NumPercent
19	14	of	IN	O	B-PP	O
19	15	patients	NNS	O	B-NP	O
19	16	who	WP	O	B-NP	O
19	17	were	VBD	O	B-VP	O
19	18	not	RB	O	O	O
19	19	too	RB	O	O	O
19	20	sick	JJ	O	O	O
19	21	to	TO	O	B-VP	O
19	22	be	VB	O	I-VP	O
19	23	fully	RB	O	I-VP	O
19	24	evaluated	VBN	O	I-VP	O
19	25	.	.	O	O	O

20	0	In	IN	O	B-PP	O
20	1	addition	NN	O	B-NP	O
20	2	to	TO	O	B-PP	O
20	3	drug-resistant	JJ	O	B-NP	O
20	4	enterococcus	NN	O	I-NP	O
20	5	bacteria	NNS	O	I-NP	B-Medical
20	6	COMMA	COMMA	O	O	O
20	7	scientists	NNS	O	B-NP	B-ProfTitle
20	8	have	VBP	O	B-VP	O
20	9	grown	VBN	O	I-VP	O
20	10	increasingly	RB	O	O	O
20	11	concerned	JJ	O	O	O
20	12	about	IN	O	B-PP	O
20	13	the	DT	O	B-NP	O
20	14	rise	NN	O	I-NP	O
20	15	of	IN	O	B-PP	O
20	16	another	DT	O	B-NP	O
20	17	microbe	NN	O	I-NP	O
20	18	COMMA	COMMA	O	O	O
20	19	staphylococcus	NN	O	B-NP	O
20	20	aureas	NN	O	I-NP	O
20	21	COMMA	COMMA	O	O	O
20	22	which	WDT	O	B-NP	O
20	23	has	VBZ	O	B-VP	O
20	24	outwitted	VBD	O	I-VP	O
20	25	most	JJS	O	B-NP	O
20	26	antibiotics	NNS	O	I-NP	O
20	27	.	.	O	O	O

21	0	Just	RB	O	B-NP	O
21	1	last	JJ	O	I-NP	O
21	2	month	NN	O	I-NP	O
21	3	COMMA	COMMA	O	O	O
21	4	the	DT	O	B-NP	O
21	5	federal	JJ	O	I-NP	O
21	6	centers	NNS	O	I-NP	O
21	7	announced	VBD	O	B-VP	O
21	8	that	IN	O	O	O
21	9	more	JJR	O	B-NP	O
21	10	than	IN	O	I-NP	O
21	11	200	CD	O	I-NP	B-Num
21	12	people	NNS	O	I-NP	O
21	13	in	IN	O	B-PP	O
21	14	North	NNP	O	B-NP	B-LocStat
21	15	Dakota	NNP	O	I-NP	I-LocStat
21	16	and	CC	O	I-NP	O
21	17	Minnesota	NNP	O	I-NP	B-LocStat
21	18	had	VBD	O	B-VP	O
21	19	become	VBN	O	I-VP	O
21	20	sick	JJ	O	O	O
21	21	COMMA	COMMA	O	O	O
21	22	and	CC	O	O	O
21	23	four	CD	O	B-NP	B-Num
21	24	children	NNS	O	I-NP	O
21	25	had	VBD	O	B-VP	O
21	26	died	VBN	O	I-VP	O
21	27	COMMA	COMMA	O	O	O
21	28	from	IN	O	B-PP	O
21	29	a	DT	O	B-NP	O
21	30	drug-resistant	JJ	O	I-NP	O
21	31	strain	NN	O	I-NP	O
21	32	of	IN	O	B-PP	O
21	33	staph	NN	O	B-NP	O
21	34	that	IN	O	B-NP	O
21	35	COMMA	COMMA	O	O	O
21	36	in	IN	O	B-PP	O
21	37	theory	NN	O	B-NP	O
21	38	COMMA	COMMA	O	O	O
21	39	should	MD	O	B-VP	O
21	40	succumb	VB	O	I-VP	O
21	41	to	TO	O	B-PP	O
21	42	vancomycin	NN	O	B-NP	O
21	43	.	.	O	O	O

22	0	The	DT	O	B-NP	O
22	1	deaths	NNS	O	I-NP	O
22	2	suggest	VBP	O	B-VP	O
22	3	that	IN	O	O	O
22	4	the	DT	O	B-NP	O
22	5	bacterium	NN	O	I-NP	O
22	6	COMMA	COMMA	O	O	O
22	7	which	WDT	O	B-NP	O
22	8	until	IN	O	B-PP	O
22	9	recently	RB	O	O	O
22	10	has	VBZ	O	B-VP	O
22	11	been	VBN	O	I-VP	O
22	12	confined	VBN	O	I-VP	O
22	13	to	TO	O	B-PP	O
22	14	hospitals	NNS	O	B-NP	O
22	15	and	CC	O	O	O
22	16	nursing	NN	O	B-NP	O
22	17	homes	NNS	O	I-NP	O
22	18	COMMA	COMMA	O	O	O
22	19	may	MD	O	B-VP	O
22	20	now	RB	O	I-VP	O
22	21	threaten	VB	O	I-VP	O
22	22	the	DT	O	B-NP	O
22	23	public	NN	O	I-NP	O
22	24	.	.	O	O	O

23	0	Rhone-Poulenc	NNP	O	B-NP	B-Peop
23	1	asked	VBD	O	B-VP	O
23	2	the	DT	O	B-NP	O
23	3	drug	NN	O	I-NP	B-Medical
23	4	agency	NN	O	I-NP	B-OrgCorp
23	5	to	TO	O	B-VP	O
23	6	approve	VB	O	I-VP	O
23	7	Synercid	NNP	O	B-NP	O
23	8	for	IN	O	B-PP	O
23	9	use	VBP	O	B-NP	O
23	10	against	IN	O	B-PP	O
23	11	these	DT	O	B-NP	O
23	12	microbes	NNS	O	I-NP	O
23	13	COMMA	COMMA	O	O	O
23	14	known	VBN	O	B-VP	O
23	15	as	IN	O	B-PP	O
23	16	methicillin-resistant	JJ	O	B-NP	O
23	17	staph	NN	O	I-NP	O
23	18	aureas	NN	O	I-NP	O
23	19	.	.	O	O	O

24	0	But	CC	O	O	O
24	1	the	DT	O	B-NP	O
24	2	agency	NN	O	I-NP	B-OrgCorp
24	3	refused	VBD	O	B-VP	O
24	4	COMMA	COMMA	O	O	O
24	5	saying	VBG	O	B-VP	O
24	6	the	DT	O	B-NP	O
24	7	company	NN	O	I-NP	B-OrgCorp
24	8	had	VBD	O	B-VP	O
24	9	not	RB	O	I-VP	O
24	10	proved	VBD	O	I-VP	O
24	11	the	DT	O	B-NP	O
24	12	drug	NN	O	I-NP	B-Medical
24	13	's	POS	O	B-NP	O
24	14	effectiveness	NN	O	I-NP	O
24	15	.	.	O	O	O

25	0	However	RB	O	O	O
25	1	COMMA	COMMA	O	O	O
25	2	the	DT	O	B-NP	O
25	3	drug	NN	O	I-NP	B-Medical
25	4	did	VBD	O	B-VP	O
25	5	win	VB	O	I-VP	O
25	6	government	NN	O	B-NP	O
25	7	approval	NN	O	I-NP	O
25	8	to	TO	O	B-VP	O
25	9	be	VB	O	I-VP	O
25	10	marketed	VBN	O	I-VP	O
25	11	for	IN	O	B-PP	O
25	12	treatment	NN	O	B-NP	O
25	13	of	IN	O	B-PP	B-Medical
25	14	skin	NN	O	B-NP	I-Medical
25	15	and	CC	O	I-NP	O
25	16	soft-tissue	JJ	O	I-NP	O
25	17	infections	NNS	O	I-NP	O
25	18	caused	VBN	O	B-VP	O
25	19	by	IN	O	B-PP	O
25	20	staph	NN	O	B-NP	O
25	21	bacteria	NNS	O	I-NP	B-Medical
25	22	COMMA	COMMA	O	O	O
25	23	as	RB	O	O	O
25	24	well	RB	O	O	O
25	25	as	IN	O	O	O
25	26	Group	NNP	O	O	B-OrgCorp
25	27	A	DT	O	B-NP	O
25	28	streptococcus	NN	O	I-NP	O
25	29	microbes	NNS	O	I-NP	O
25	30	COMMA	COMMA	O	O	O
25	31	that	DT	O	B-NP	O
25	32	are	VBP	O	B-VP	O
25	33	susceptible	JJ	O	O	O
25	34	to	TO	O	B-PP	O
25	35	other	JJ	O	B-NP	O
25	36	medications	NNS	O	I-NP	O
25	37	.	.	O	O	O

26	0	The	DT	O	B-NP	O
26	1	big	JJ	O	I-NP	O
26	2	question	NN	O	I-NP	O
26	3	about	IN	O	B-PP	O
26	4	Synercid	NNP	O	B-NP	O
26	5	is	VBZ	O	B-VP	O
26	6	whether	IN	O	O	O
26	7	COMMA	COMMA	O	O	O
26	8	or	CC	O	O	O
26	9	when	WRB	O	O	O
26	10	COMMA	COMMA	O	O	O
26	11	widespread	JJ	O	B-NP	O
26	12	resistance	NN	O	I-NP	O
26	13	will	MD	O	B-VP	O
26	14	develop	VB	O	I-VP	O
26	15	to	TO	O	B-PP	O
26	16	it	PRP	O	B-NP	O
26	17	.	.	O	O	O

27	0	Virginiamycin	NNP	O	B-NP	B-Peop
27	1	COMMA	COMMA	O	O	O
27	2	a	DT	O	B-NP	O
27	3	chemical	NN	O	I-NP	B-Medical
27	4	cousin	NN	O	I-NP	O
27	5	of	IN	O	B-PP	O
27	6	Synercid	NNP	O	B-NP	O
27	7	COMMA	COMMA	O	O	O
27	8	has	VBZ	O	B-VP	O
27	9	been	VBN	O	I-VP	O
27	10	used	VBN	O	I-VP	O
27	11	over	IN	O	B-PP	O
27	12	the	DT	O	B-NP	O
27	13	past	JJ	O	I-NP	O
27	14	decade	NN	O	I-NP	O
27	15	to	TO	O	B-VP	O
27	16	promote	VB	O	I-VP	O
27	17	growth	NN	O	B-NP	O
27	18	in	IN	O	B-PP	O
27	19	animals	NNS	O	B-NP	B-Animal
27	20	COMMA	COMMA	O	O	O
27	21	and	CC	O	O	O
27	22	some	DT	O	B-NP	O
27	23	experts	NNS	O	I-NP	O
27	24	say	VBP	O	B-VP	O
27	25	it	PRP	O	B-NP	O
27	26	is	VBZ	O	B-VP	O
27	27	only	RB	O	B-NP	O
27	28	a	DT	O	I-NP	O
27	29	matter	NN	O	I-NP	O
27	30	of	IN	O	B-PP	O
27	31	time	NN	O	B-NP	O
27	32	before	IN	O	O	O
27	33	resistance	NN	O	B-NP	O
27	34	to	TO	O	B-PP	O
27	35	Synercid	NNP	O	B-NP	B-Peop
27	36	will	MD	O	B-VP	O
27	37	develop	VB	O	I-VP	O
27	38	.	.	O	O	O

28	0	``	``	O	O	O
28	1	It	PRP	O	B-NP	O
28	2	's	VBZ	O	B-VP	O
28	3	not	RB	O	O	O
28	4	the	DT	O	B-NP	O
28	5	answerCOMMA	NN	O	I-NP	O
28	6	''	''	O	O	O
28	7	Dr.	NNP	O	B-NP	B-ProfTitle
28	8	Stuart	NNP	O	I-NP	B-Peop
28	9	B.	NNP	O	I-NP	I-Peop
28	10	Levy	NNP	O	I-NP	I-Peop
28	11	COMMA	COMMA	O	O	O
28	12	an	DT	O	B-NP	O
28	13	expert	NN	O	I-NP	O
28	14	in	IN	O	B-PP	O
28	15	antibiotic	NN	O	B-NP	B-Medical
28	16	resistance	NN	O	I-NP	O
28	17	at	IN	O	B-PP	O
28	18	Tufts	NNP	O	B-NP	B-OrgUniv
28	19	University	NNP	O	I-NP	I-OrgUniv
28	20	COMMA	COMMA	O	O	O
28	21	said	VBD	O	B-VP	O
28	22	of	IN	O	B-PP	O
28	23	Synercid	NNP	O	B-NP	B-Peop
28	24	.	.	O	O	O

29	0	``	``	O	O	O
29	1	It	PRP	O	B-NP	O
29	2	is	VBZ	O	B-VP	O
29	3	just	RB	O	B-NP	O
29	4	a	DT	O	I-NP	O
29	5	temporary	JJ	O	I-NP	O
29	6	Band-Aid	NNP	O	I-NP	O
29	7	.	.	O	O	O
29	8	''	''	O	O	O
